Banfi Giuseppe, Del Fabbro Massimo
IRCCS Galeazzi, Milano, Italy.
Semin Thromb Hemost. 2008 Oct;34(7):635-41. doi: 10.1055/s-0028-1104541. Epub 2008 Dec 15.
The two components of biological variability are interindividual variability, which is the variability due to the heterogeneity of physiologic influences among subjects, and intraindividual variability, which is due to the variability in the same individual over time. Analysis of biological variation is crucial for estimating the critical difference, which corresponds with a threshold suggestive of a statistically significant difference between two consecutive results of a laboratory parameter in the same subject and is therefore unlikely attributable to casual (random) oscillation of values. Studies on biological variation of tests of hemostasis are outdated, and the published results should be confirmed by using modern, fully automated methods. Biological variation for coagulation screening tests (prothrombin time and activated partial thromboplastin time) is low and comparable with the values registered for hematologic parameters. However, the index of individuality (ratio between intraindividual and interindividual variability) suggests that the usual preoperative screening for coagulation disorders is influenced by the between-subjects variability. Thrombin time is very constant within and between subjects. Proteins such as fibrinogen, clotting factors, and antithrombin show a low biological variability. In contrast, fibrinolytic parameters, such as plasminogen activator inhibitor 1 and fibrinopeptide A, show very high variability, and their interpretation in the clinical setting must take this into consideration.
生物变异性的两个组成部分是个体间变异性,即由于个体间生理影响的异质性导致的变异性,以及个体内变异性,即同一人随时间变化的变异性。生物变异分析对于估计临界差异至关重要,临界差异对应于一个阈值,该阈值表明同一受试者实验室参数的两个连续结果之间存在统计学上的显著差异,因此不太可能归因于数值的偶然(随机)波动。关于止血检测生物变异的研究已经过时,发表的结果应使用现代全自动方法进行确认。凝血筛查试验(凝血酶原时间和活化部分凝血活酶时间)的生物变异较低,与血液学参数记录的值相当。然而,个体性指数(个体内变异性与个体间变异性之比)表明,通常的术前凝血障碍筛查受个体间变异性的影响。凝血酶时间在个体内和个体间都非常稳定。纤维蛋白原、凝血因子和抗凝血酶等蛋白质的生物变异性较低。相比之下,纤溶参数,如纤溶酶原激活物抑制剂1和纤维肽A,显示出非常高的变异性,在临床环境中对它们的解释必须考虑到这一点。